search
Back to results

Comparison of Efficacy of ESWL and Laser Lithotripsy in Chronic Pancreatitis With ERCP

Primary Purpose

Pancreatitis, Chronic, Pancreatic Duct Stone

Status
Not yet recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
ESWL and ERCP
LL and ERCP
Sponsored by
Changhai Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pancreatitis, Chronic focused on measuring Cholangiopancreatography, Endoscopic Retrograde, Lithotripsy

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • symptomatic adult patients diagnosed with chronic pancreatitis and pancreatic duct stones;
  • at least one stone (>5 mm in diameter) located in the pancreatic duct of the head/body of the pancreas;
  • dilation of the proximal pancreatic duct.

Exclusion Criteria:

  • history of ERCP or ESWL treatment;
  • suspected to have malignant tumors;
  • history of pancreatic surgery or gastrojejunostomy (Billroth II);
  • pancreatic pseudocyst with a diameter >4cm;
  • bile duct stricture secondary to cholangitis or chronic pancreatitis;
  • acute pancreatitis exacerbation or acute exacerbation of chronic pancreatitis (including biliary pancreatitis);
  • coagulation dysfunction (INR≥1.5 or platelet count≤50×10^9/L);
  • pregnant or breastfeeding women;
  • patients who refused to participate in the study.

Sites / Locations

  • Changhai Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

ESWL and ERCP

LL and ERCP

Arm Description

The patients will receive intravenous analgesia (flurbiprofen and remifentanil) before the ESWL (Compact Delta II; Dornier Med Tech, Wessling, Germany). The time scale between the last ESWL session and following ERCP will be greater than 48h. ERCP will be performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, endoscopic sphincterotomy will be performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. Standard techniques (i.e., extraction basket, extraction balloon, or both) will be used for stone removal. A pancreatic duct stent or a nasopancreatic catheter will be inserted for temporary drainage if necessary.

ERCP will be performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, endoscopic sphincterotomy will be performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. After that, laser lithotripsy will be performed. Standard techniques (i.e., extraction basket, extraction balloon, or both) will be used for stone removal. A pancreatic duct stent or a nasopancreatic catheter will be inserted for temporary drainage if necessary.

Outcomes

Primary Outcome Measures

technical success rates
Technical success rates refer to the successful completion of standard procedures or the occurrence of complete spontaneous stone removal.
clearance rates of pancreatic duct stones
Clearance rates have been defined as complete, partial, or failure if the proportion of stones cleared was > 90%, 50% - 90%, or < 50%, respectively.

Secondary Outcome Measures

time taken to completely clear the stone
The time taken to completely clear the stones.
postoperative complications
Major post-ERCP complications includes post-ERCP pancreatitis, bleeding, infection, and perforation, which are classified as mild, moderate, or severe, depending mainly on the length of hospitalization and the need for invasive treatment.
success rates of pancreatic duct decompression
Successful removal of pancreatic duct obstruction factors by clearing stones and/or placing pancreatic duct stents/nasopancreatic catheters.

Full Information

First Posted
April 6, 2022
Last Updated
September 13, 2022
Sponsor
Changhai Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05326542
Brief Title
Comparison of Efficacy of ESWL and Laser Lithotripsy in Chronic Pancreatitis With ERCP
Official Title
ESWL Combined With ERCP and Laser Lithotripsy Combined With ERCP In Treatment of Pancreatic Duct Stones With Chronic Pancreatitis: a Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
September 2022 (Anticipated)
Primary Completion Date
October 2022 (Anticipated)
Study Completion Date
December 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Changhai Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study will compare the efficacy of ESWL and Laser Lithotripsy in the treatment of pancreatic duct stones with ERCP.
Detailed Description
Chronic pancreatitis (CP) is an inflammatory disease that can causes progressive fibrosis of pancreatic tissue and eventually leads to damage of pancreatic exocrine and endocrine. According to statistics, the prevalence of CP in China is 13/10 million, which is still increasing. Pancreatic duct stones are the most important pathological changes of CP. More than 50% of patients with CP are accompanied by pancreatic duct stones, which can lead to pancreatic duct obstruction, hypertension and tissue ischemia. Removal of pancreatic duct stones under Endoscopic Retrograde Cholangiopancreatography (ERCP) are the first choice. ERCP is effective in the treatment of pancreatic duct stones by using basket and/or balloon catheter. But in most cases, ERCP is only suitable for the treatment of pancreatic duct stones (diameter < 5mm) located in the head/body of the Pancreatic Duct (PD). PD stones larger than 5mm generally require Extracorporeal Shock Wave Lithotripsy (ESWL) or Endoscopic Intraductal Lithotripsy (EIL) for pretreatment. EIL includes Electrohydraulic Lithotripsy (EHL) and Laser Lithotripsy (LL). ESWL first locates the stone by X-ray, and then uses an electromagnetic pulse generator to direct a higher-energy shock wave to the stone, so that the stone is crushed by thousands of shock waves. The principle of laser lithotripsy is to make the stone absorb strong infrared rays and generate shock waves to achieve the purpose of fragmenting the stone. In view of the fact that there is no relevant research comparing the overall efficacy of ESWL combined with ERCP and EIL combined with ERCP, it is necessary to evaluate the differences in the therapeutic effects and complications of the two for PD stones. This research helps to provide evidence-based medical evidence, guide physicians' clinical practice, improve the quality of patients' lives, and reduce the economic burden of patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pancreatitis, Chronic, Pancreatic Duct Stone
Keywords
Cholangiopancreatography, Endoscopic Retrograde, Lithotripsy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
ESWL and ERCP
Arm Type
Experimental
Arm Description
The patients will receive intravenous analgesia (flurbiprofen and remifentanil) before the ESWL (Compact Delta II; Dornier Med Tech, Wessling, Germany). The time scale between the last ESWL session and following ERCP will be greater than 48h. ERCP will be performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, endoscopic sphincterotomy will be performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. Standard techniques (i.e., extraction basket, extraction balloon, or both) will be used for stone removal. A pancreatic duct stent or a nasopancreatic catheter will be inserted for temporary drainage if necessary.
Arm Title
LL and ERCP
Arm Type
Active Comparator
Arm Description
ERCP will be performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, endoscopic sphincterotomy will be performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. After that, laser lithotripsy will be performed. Standard techniques (i.e., extraction basket, extraction balloon, or both) will be used for stone removal. A pancreatic duct stent or a nasopancreatic catheter will be inserted for temporary drainage if necessary.
Intervention Type
Procedure
Intervention Name(s)
ESWL and ERCP
Intervention Description
First, ESWL will be used for lithotripsy, and then ERCP will be performed to clear the stones after lithotripsy.
Intervention Type
Procedure
Intervention Name(s)
LL and ERCP
Intervention Description
After establishing the working channel under ERCP, the stone will be crushed with a laser lithotripter, and then ERCP will clear the stones after lithotripsy.
Primary Outcome Measure Information:
Title
technical success rates
Description
Technical success rates refer to the successful completion of standard procedures or the occurrence of complete spontaneous stone removal.
Time Frame
during ERCP procedure
Title
clearance rates of pancreatic duct stones
Description
Clearance rates have been defined as complete, partial, or failure if the proportion of stones cleared was > 90%, 50% - 90%, or < 50%, respectively.
Time Frame
during ERCP procedure
Secondary Outcome Measure Information:
Title
time taken to completely clear the stone
Description
The time taken to completely clear the stones.
Time Frame
during ESWL and ERCP procedure
Title
postoperative complications
Description
Major post-ERCP complications includes post-ERCP pancreatitis, bleeding, infection, and perforation, which are classified as mild, moderate, or severe, depending mainly on the length of hospitalization and the need for invasive treatment.
Time Frame
30 days after ERCP procedure
Title
success rates of pancreatic duct decompression
Description
Successful removal of pancreatic duct obstruction factors by clearing stones and/or placing pancreatic duct stents/nasopancreatic catheters.
Time Frame
during ERCP procedure
Other Pre-specified Outcome Measures:
Title
abdominal pain relief rate
Description
Postoperative and preoperative abdominal pain was assessed using the Visual Analogue Scale (VAS). VAS can be calculated ranging from 0 (no pain) to 100 (severe pain).
Time Frame
30 days after ERCP procedure

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: symptomatic adult patients diagnosed with chronic pancreatitis and pancreatic duct stones; at least one stone (>5 mm in diameter) located in the pancreatic duct of the head/body of the pancreas; dilation of the proximal pancreatic duct. Exclusion Criteria: history of ERCP or ESWL treatment; suspected to have malignant tumors; history of pancreatic surgery or gastrojejunostomy (Billroth II); pancreatic pseudocyst with a diameter >4cm; bile duct stricture secondary to cholangitis or chronic pancreatitis; acute pancreatitis exacerbation or acute exacerbation of chronic pancreatitis (including biliary pancreatitis); coagulation dysfunction (INR≥1.5 or platelet count≤50×10^9/L); pregnant or breastfeeding women; patients who refused to participate in the study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Liang-hao Hu, MD
Phone
+86-13817593520
Email
ianghao-hu@smmu.edu.cn
First Name & Middle Initial & Last Name or Official Title & Degree
Zhao-shen Li, MD
Phone
+86-13901960921
Email
zhaoshen-li@hotmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Liang-hao Hu, MD
Organizational Affiliation
Changhai Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Changhai Hospital
City
Shanghai
ZIP/Postal Code
200433
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Liang-hao Hu, MD
Phone
+86-13817593520
Email
lianghao-hu@smmu.edu.cn
First Name & Middle Initial & Last Name & Degree
Zhao-shen Li, MD
Phone
+86-13901960921
Email
zhaoshen-li@hotmail.com
First Name & Middle Initial & Last Name & Degree
Yi-li Cai, MD
First Name & Middle Initial & Last Name & Degree
Dan Wang, MD
First Name & Middle Initial & Last Name & Degree
Teng Wang, MD

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
31238312
Citation
Hao L, Liu Y, Xie T, Wang T, Guo HL, Pan J, Wang D, Bi YW, Ji JT, Xin L, Du TT, Lin JH, Zhang D, Zeng XP, Zou WB, Chen H, Li BR, Liao Z, Cong ZJ, Shi RH, Li ZS, Hu LH. Risk Factors and Nomogram for Pancreatic Stone Formation in Chronic Pancreatitis over a Long-Term Course: A Cohort of 2,153 Patients. Digestion. 2020;101(4):473-483. doi: 10.1159/000500941. Epub 2019 Jun 25.
Results Reference
background

Learn more about this trial

Comparison of Efficacy of ESWL and Laser Lithotripsy in Chronic Pancreatitis With ERCP

We'll reach out to this number within 24 hrs